Full Title
A Decentralized Randomized Dietary Trial in Newly Diagnosed Multiple Myeloma - NUTRIVENTION5Purpose
Researchers want to see if dietary changes can affect chemotherapy response or quality of life in people newly diagnosed with multiple myeloma. The people in this study are receiving standard induction (initial) chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone (DRVd).
The dietary intervention is plant-based, dairy-free, animal-free, and not certified kosher. Research in other groups has shown that this diet may promote weight loss, improve hormonal balance, and reduce inflammation in the body. Researchers want to know if this will happen in people with newly diagnosed multiple myeloma.
If you take part in this study, you will be randomly assigned to one of these groups:
- Intervention arm: While receiving standard induction chemotherapy, you will receive prepared, frozen plant-based meals for 12 weeks. You will also have a phone call or video call with a dietitian every 2 weeks for 12 weeks.
- Usual care arm: While receiving standard induction chemotherapy, you will have phone calls with a member of the study team every 4 weeks. At the end of standard induction chemotherapy, you will have a phone call or video call with a dietitian. You will also have the option to receive a $200 gift card.
Who Can Join
To join this study, there are a few conditions. You must:
- Be newly diagnosed with multiple myeloma.
- Be planning to start standard DRVd induction chemotherapy either at Memorial Sloan Kettering or at a site that uses EPIC for electronic medical records and is willing to share records with MSK.
- Currently not be following a whole-food plant-based diet.
- Have a body mass index (BMI) of 20 or more.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please email [email protected].